Global Molecular Diagnostics for Infectious Disease Market Report 2021-2025: Microbiology Lab May Disappear While Multiplex Takes Center Stage
05 mai 2021 04h53 HE
|
Research and Markets
Dublin, May 05, 2021 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Infectious Disease 2021-2025: Market Analysis by Syndrome, Plex, Place, and Country with COVID-19 Impact & Forecast,...
Molecular Diagnostics for Infectious Disease Markets, 2025 - C19Dx Demand Sweeps Over the Globe
29 janv. 2021 04h13 HE
|
Research and Markets
Dublin, Jan. 29, 2021 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With COVID-19 Impact & Forecasting/Analysis, and Executive...
The Global Market for Molecular Diagnostics Infectious Disease 2021-2025
24 nov. 2020 17h23 HE
|
Research and Markets
Dublin, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With COVID-19 Impact & Forecasting/Analysis, and Executive...
ContraFect Announces Plan for a Single Phase 3 Superiority Design Study of Exebacase Following Successful End-of-Phase 2 Meeting with FDA
02 oct. 2019 07h00 HE
|
ContraFect Corporation
Primary Endpoint of Clinical Response at Day 14 in Patients with Methicillin-Resistant Staph aureus (MRSA) Bacteremia, including Right-Sided Endocarditis Study Initiation Planned by Year-End 2019 ...
ContraFect Awarded $7.2 Million USAMRDC Grant to Support the Advancement of Lysin Candidate CF-296
06 juin 2019 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., June 06, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect Announces Presentation at the International Society of Cardiovascular Infectious Diseases Symposium
03 juin 2019 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., June 03, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect Announces Publication of Paper on Recent Exebacase Data in Antimicrobial Agents and Chemotherapy Journal
31 mai 2019 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., May 31, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect to Present at Cantor Antibiotics Summit
11 janv. 2018 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Jan. 11, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present at 10th Annual Biotech Showcase
03 janv. 2018 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Jan. 03, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect to Present at the 29th Annual Piper Jaffray Healthcare Conference
15 nov. 2017 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Nov. 15, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...